$TLSI News
Last published 1d ago
- 1d agoTLSIThird Quarter 2026 Earnings Call - TRISALUS LIFE SCIENCES INCEarnings Call TranscriptsThank you for standing by. My name is Kate, and I'll be your conference operator today. At this time, I would like to welcome to the Tricellus Live Appliances third quarter 2026 earnings call. All lines have been placed
- 1d agoTLSITriSalus Life Sciences, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoTLSITriSalus Life Sciences Reports Third Quarter 2026 ResultsBusiness WireDENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended September 30, 2026, and provided an operational update. “The third qua ...
- 1w agoTLSITriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services ForumBusiness WireTriSalus Life Sciences® Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients
- 3w agoTLSITriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference CallBusiness WireTriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform
- 1mo agoTLSITriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver EmbolizationBusiness WireTriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform
- 2mo agoTLSITriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment ConferenceBusiness WireTriSalus Life Sciences® Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients
- 3mo agoTLSICG 46TH ANNUAL GROWTH CONFERENCE - TRISALUS LIFE SCIENCES INCEarnings Call TranscriptsGood morning. My name is Bill Blavonic. I'm a senior analyst here with Canaccord Genuity. Welcome to our 46th annual Global Growth Conference. I'm one of the senior med tech analysts here. With us next, we're going to ha
- 3mo agoTLSICG 46TH ANNUAL GROWTH CONFERENCE - TRISALUS LIFE SCIENCES INCEarnings Call TranscriptsGood morning. My name is Bill Blavonic. I'm a senior analyst here with Canaccord Genuity. Welcome to our 46th annual Global Growth Conference. I'm one of the senior med tech analysts here. With us next, we're going to ha
- 3mo agoTLSITriSalus Life Sciences Reports Second Quarter 2026 ResultsBusiness WireGenerated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration Maintains 2026 revenue guidance of $54 million to $57 million Hosting
- 3mo agoTLSITriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth ConferenceBusiness WireTriSalus Life Sciences® Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients
- 3mo agoTLSITriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference CallBusiness WireTriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform
- 5mo agoTLSITriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver CancerBusiness WireNewly published study demonstrates 48% improvement in drug delivery with PEDD™; sicker patients experienced fewer adverse events, 61% reduced hospital readmissions. Leading interventional oncologist to share
- 6mo agoTLSITriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term GrowthBusiness WireGenerated first quarter revenue of $8.9 million and expanded commercial organization to support future growth and broader market penetration Published landmark, real-world PEDD® Study of 603 PEDD patients and
- 6mo agoTLSIReal-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge AvoidanceBusiness WireStudy of 603 PEDD patients and 16,210 non-PEDD patients found PEDD technology was associated with fewer post-procedure complications, reduced hospitalizations, and approximately $7,700 in per-patient charge avoidance
- 6mo agoTLSITriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver TumorsBusiness WireTriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for
- 6mo agoTLSITriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference CallBusiness WireConference Call and Webcast Scheduled for Tuesday, May 12, 2026 at 4:30 PM TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care
- 7mo agoTLSITriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific MeetingBusiness WireTriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for
- 7mo agoTLSITriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical OfficerBusiness WireTriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for
- 7mo agoTLSITriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor ModelsBusiness WireTriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for
- 8mo agoTLSITriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue GuidanceBusiness WireReports $13.2 million in Revenue in the Fourth Quarter, $45.2 million for Full-Year of 2025, Representing increases of 60% and 53%, respectively, Versus the Prior Year Periods Reaffirms 2026 Revenue Guidance of $60-62
- 8mo agoTLSITriSalus Life Sciences Announces Pricing of $40.0 Million Public OfferingBusiness WireTriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve
- 8mo agoTLSITriSalus Life Sciences Proposes Public OfferingBusiness WireTriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve
- 9mo agoTLSITriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of DirectorsBusiness WireTriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve
- 10mo agoTLSITriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue GuidanceBusiness WireFourth quarter 2025 revenue of approximately $13.2 million, Up 60% Year-Over-Year Full-year 2025 revenue growth of approximately 53% exceeded 2025 guidance Set initial 2026 revenue guidance of approximately $60-$62
- 11mo agoTLSITriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025Business WireTriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors,
- 11mo agoTLSITriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™Business WireTriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the launch of the
- 12mo agoTLSITriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue GuidanceBusiness WireTriSalus Reports $11.6 million in Revenue, Up 57% Year-over-Year, Reflecting Strong Liver Embolization growth Investigator Published Data Show TriNav Enables Safe, Effective Thyroid Embolization Alternative to
- 1y agoTLSITriSalus Life Sciences to Participate in Upcoming Investor ConferencesBusiness WireTriSalus Life Sciences® Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid
- 1y agoTLSITriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025Business WireTriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors,
- 1y agoTLSITriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference CallBusiness WireConference Call and Webcast Scheduled for Thursday November 13, 2025 at 4:30 PM TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with
- 1y agoTLSITriSalus Life Sciences to Participate in Upcoming September Investor ConferencesBusiness WireTriSalus Life Sciences® Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid
- 1y agoTLSITriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoTLSITriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 GuidanceBusiness WireCompany delivers $11.2M in revenues resulting in 52% growth year-over-year and 22% growth quarter-over-quarter Broadened PEDD portfolio with launch of TriNav FLX designed to improve access in tortuous vessels Confirming
- 1y agoTLSITriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization TechniqueBusiness WireTriSalus Life Sciences® Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid
- 1y agoTLSITriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth ConferenceBusiness WireTriSalus Life Sciences® Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, today announced that Mary Szela,
- 1y agoTLSITriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference CallBusiness WireConference Call and Webcast Scheduled for Tuesday August 12, 2025 at 4:30 PM TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), a company working to improve outcomes for patients with solid
- 1y agoTLSITriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred StockBusiness WireTriSalus Life Sciences® Inc. (NASDAQ:TLSI), a company focused on improving outcomes for patients with solid tumors, announced the completion of its previously disclosed exchange offer and consent solicitation for
- 1y agoTLSITriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital StructureBusiness WireTriSalus Life Sciences® Inc. (NASDAQ:TLSI), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on-market therapeutics and immunotherapy ("TriSalus"
- 1y agoTLSITriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion SystemBusiness WireTriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care
- 1y agoTLSITriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. PatienceBusiness WireDavid Patience, an accomplished healthcare CFO with deep experience in the life sciences sector, appointed as CFO effective July 1, 2025 Current CFO James E. Young steps down; Dan Giordano, Vice President of Finance,
- 1y agoTLSITriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 GuidanceBusiness WireCompany delivers 42% revenue growth year-over-year and strengthens balance sheet with $22 million gross proceeds from recent private placement Expands commercial footprint, and invests further in new applications for
- 1y agoTLSITriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference CallBusiness WireConference Call and Webcast Scheduled for Thursday May 15, 2025 at 8:00 AM TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for
- 1y agoTLSITriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial ResultsBusiness WireFunding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Anticipated Preferred Stock Exchange to Simplify Capital Structure Private Placement Expected to Fund Business to
- 1y agoTLSITriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business UpdateBusiness WireRevenues of $8.3 Million in Q4 and $29.4 Million for Full-Year 2024, Representing Growth of 44% And 59%, Respectively, Versus the Prior Year Periods Gross Margin of 85% and 86% for Q4 and Full-Year
- 1y agoTLSITriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System MappingBusiness WireTriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care
- 1y agoTLSITriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of "Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model"Business WireTriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), TriSalus Life Sciences, which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology
- 1y agoTLSITriSalus Life Sciences Announces Key Appointments to Board of DirectorsBusiness WireHealthCare Industry Veterans William Valle and Gary Gordon, M.D. add Strategic Expertise in Medical Devices, Reimbursement, and Pancreatic Cancers TriSalus Life Sciences® Inc. (NASDAQ:TLSI), a biomedical
- 1y agoTLSITriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMedBusiness WireTriSalus Life Sciences® Inc. (NASDAQ:TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care
- 1y agoTLSITriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference CallBusiness WireQ4 Revenue of approximately $8.3 million represents approximately 44% growth versus Q4 2023 Full year 2024 Revenue of approximately $29.4 million represent approximately 59% growth versus full year 2023 Q4